Last edition
News about "Cipla Pharma and Life Sciences"
Maharashtra FDA Cancels Cipla Pharma's C&F Drug Licences in Pune Over Regulatory Violations
Maharashtra FDA has cancelled Cipla Pharma & Life Sciences’ C&F drug sale and distribution licences at Vadki, Pune, citing violations linked to misbranded ‘Reactin Plus’ tablets, storage deficiencies, inventory discrepancies and non-compliance with recall directions.
Cipla Pharma And Life Sciences | 31/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members